Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment

被引：1

作者：

Lenz, Heinz-Josef

Yoshino, Takayuki

Argiles, Guillem

Iveson, Timothy

Sastre, Javier

Harrison, Mark

Lim, Howard John

Tebbutt, Niall C.

Peeters, Marc

Satoh, Taroh

Dittrich, Christian

Sassi, Mouna

Loembe, Arsene-Bienvenu

Van Cutsem, Eric

机构：

[1] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[2] Natl Canc Ctr Hosp East, Chiba, Japan

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain

[5] Southampton Gen Hosp, Southampton, Hants, England

[6] Hosp Clin San Carlos, Madrid, Spain

[7] Mt Vernon Hosp, Northwood, Middx, England

[8] BC Canc Agcy, Vancouver Ctr, Div Med Oncol, Vancouver, BC, Canada

[9] Austin Hlth, Melbourne, Vic, Australia

[10] Univ Antwerp Hosp, Edegem, Belgium

[11] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan

[12] ACR ITR VIEnna, Vienna, Austria

[13] Kaiser Franz Josef Spital, Ctr Oncol & Haematol, Vienna, Austria

[14] Boehringer Ingelheim France, Reims, France

[15] Boehringer Ingelheim BV, Alkmaar, Netherlands

[16] Univ Hosp Leuven, Leuven, Belgium

来源：

关键词：

D O I：

10.1200/JCO.2017.35.4_suppl.660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

660

引用

页数：2